Open Peer Review on Qeios

Anlotinib

National Cancer Institute

Source

National Cancer Institute. <u>Anlotinib</u>. NCI Thesaurus. Code C138997.

A receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and antiangiogenic activities. Upon administration, anlotininib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.